An M.D.-Ph.D. candidate in Georgetown University’s tumor biology program defended his dissertation, titled “Molecular Signatures of Treatment Responses in Tumors and Serial Liquid Biopsies in Patients with Metastatic Melanoma,” Jan. 16.
Of Interest
Nevus-Associated Acral Melanoma Has Better Survival Outcomes Than De Novo
Nevus-associated acral melanoma (NAAM) demonstrates better recurrence-free survival and overall survival compared with de novo acral melanoma (DNAM), indicating a potentially more favorable prognosis for patients with NAAM, according to study results published in the Journal of the American Academy of Dermatology.
Dabrafenib-Trametinib Combo Shows Activity as Second-Line Adjuvant Therapy in Advanced Melanoma
Second-line adjuvant treatment with dabrafenib and trametinib appeared effective in a small study of patients with BRAF V600-mutated, resected, stage III/IV melanoma, researchers found. In fact, more than 80% of patients were free from relapse and metastasis at 1 year. These results were published in The Oncologist.
BMS-986253 Plus Nivolumab/Ipilimumab Fails to Boost Responses in Advanced Melanoma After Prior Anti–PD-(L)1 Therapy
BMS-986253 plus nivolumab/ipilimumab failed to improve responses or PFS in advanced melanoma after progression on or after a checkpoint inhibitor.